Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Lin

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
BMJ Oncology|January 31, 2025
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trialsAlexander D Sherry, Pavlos Msaouel, Timothy A Lin, et al.
Mayo Clinic Proceedings|February 7, 2021
Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled TrialsDario Pasalic, C David Fuller, Walker Mainwaring, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2024
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor TrialsAlexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
NPJ Precision Oncology|July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
The Oncologist|April 10, 2020
Exclusion of Men from Randomized Phase III Breast Cancer Clinical TrialsKelsey L Corrigan, Walker Mainwaring, Austin B Miller, et al.
International Journal of Cancer|August 14, 2024
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trialsAlexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2025
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology TrialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
JAMA Network Open|May 17, 2023
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical TrialsMarcus A Florez, Joseph Abi Jaoude, Roshal R Patel, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Cancers|September 19, 2020
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical TrialsTimothy A Lin, Clifton David Fuller, Vivek Verma, et al.
JAMA Oncology|June 1, 2025
Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological AnalysisAlexander D Sherry, Avital M Miller, Jnana Preeti Parlapalli, et al.
BMJ Oncology|January 31, 2025
Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trialsAlexander D Sherry, Pavlos Msaouel, Timothy A Lin, et al.
Mayo Clinic Proceedings|February 7, 2021
Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled TrialsDario Pasalic, C David Fuller, Walker Mainwaring, et al.
International Journal of Radiation Oncology, Biology, Physics|October 1, 2024
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor TrialsAlexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
NPJ Precision Oncology|July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
The Oncologist|April 10, 2020
Exclusion of Men from Randomized Phase III Breast Cancer Clinical TrialsKelsey L Corrigan, Walker Mainwaring, Austin B Miller, et al.
International Journal of Cancer|August 14, 2024
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trialsAlexander D Sherry, Timothy A Lin, Zachary R McCaw, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2025
Survival-Inferred Fragility of Statistical Significance in Phase III Oncology TrialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
JAMA Network Open|May 17, 2023
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical TrialsMarcus A Florez, Joseph Abi Jaoude, Roshal R Patel, et al.
Pageof 6